A high throughput MHC II binding assay for quantitative analysis of peptide epitopes.
暂无分享,去创建一个
Chris Bailey-Kellogg | Karl E Griswold | Leonard Moise | Regina Salvat | Regina S. Salvat | C. Bailey-Kellogg | K. Griswold | L. Moise
[1] W. Martin,et al. De-immunization of therapeutic proteins by T-cell epitope modification. , 2005, Developments in biologicals.
[2] R. Rappuoli,et al. Developing vaccines in the era of genomics: a decade of reverse vaccinology. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[3] A. D. De Groot,et al. Harnessing the power of genomics and immunoinformatics to produce improved vaccines , 2011, Expert opinion on drug discovery.
[4] U. Şahin,et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices , 1999, Nature Biotechnology.
[5] Chris Bailey-Kellogg,et al. Structure‐based redesign of proteins for minimal T‐cell epitope content , 2013, J. Comput. Chem..
[6] G. Li Pira,et al. High Throughput T Epitope Mapping and Vaccine Development , 2010, Journal of biomedicine & biotechnology.
[7] Julie A McMurry,et al. In silico-accelerated identification of conserved and immunogenic variola/vaccinia T-cell epitopes. , 2009, Vaccine.
[8] Anne S De Groot,et al. Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. , 2009, Clinical immunology.
[9] Chris Bailey-Kellogg,et al. Open Access Methodology Article Optimization Algorithms for Functional Deimmunization of Therapeutic Proteins , 2022 .
[10] Ira Mellman,et al. Cell biology of antigen processing in vitro and in vivo. , 2005, Annual review of immunology.
[11] O. Lund,et al. NetMHCIIpan-2.0 - Improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure , 2010, Immunome research.
[12] William W. Kwok,et al. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide , 2006, The Journal of experimental medicine.
[13] L Raddrizzani,et al. Different modes of peptide interaction enable HLA-DQ and HLA-DR molecules to bind diverse peptide repertoires. , 1997, Journal of immunology.
[14] Ji Wan,et al. SVRMHC prediction server for MHC-binding peptides , 2006, BMC Bioinformatics.
[15] Chris Bailey-Kellogg,et al. Structure-Guided Deimmunization of Therapeutic Proteins , 2012, RECOMB.
[16] Søren Buus,et al. Functional recombinant MHC class II molecules and high-throughput peptide-binding assays , 2009, Immunome research.
[17] M. Roederer,et al. Measuring Ag-specific immune responses: understanding immunopathogenesis and improving diagnostics in infectious disease, autoimmunity and cancer. , 2005, Trends in immunology.
[18] Gajendra P. S. Raghava,et al. ProPred: prediction of HLA-DR binding sites , 2001, Bioinform..
[19] Chris Bailey-Kellogg,et al. Optimization of Therapeutic proteins to Delete T-Cell epitopes while Maintaining Beneficial Residue Interactions , 2011, J. Bioinform. Comput. Biol..
[20] Wei Jiang,et al. High-throughput engineering and analysis of peptide binding to class II MHC , 2010, Proceedings of the National Academy of Sciences.
[21] Biologic drugs set to top 2012 sales , 2012, Nature Medicine.
[22] L. Picker,et al. Mapping T cell epitopes by flow cytometry. , 2003, Methods.
[23] Alessandro Sette,et al. Reverse vaccinology: developing vaccines in the era of genomics. , 2010, Immunity.
[24] Pingping Guan,et al. MHCPred: bringing a quantitative dimension to the online prediction of MHC binding. , 2003, Applied bioinformatics.
[25] Saurabh Aggarwal,et al. What's fueling the biotech engine—2011 to 2012 , 2012, Nature Biotechnology.
[26] John Sidney,et al. A Systematic Assessment of MHC Class II Peptide Binding Predictions and Evaluation of a Consensus Approach , 2008, PLoS Comput. Biol..
[27] Leonard Moise,et al. Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo. , 2012, Clinical immunology.
[28] T. Baglin,et al. Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII , 2005, Journal of thrombosis and haemostasis : JTH.
[29] Morten Nielsen,et al. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method , 2007, BMC Bioinformatics.
[30] Marc De Maeyer,et al. Elimination of a Human T-cell Region in Staphylokinase by T-cell Screening and Computer Modeling , 2002, Thrombosis and Haemostasis.
[31] Bjoern Peters,et al. Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications , 2005, Immunogenetics.
[32] George Georgiou,et al. Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift , 2011, Proceedings of the National Academy of Sciences.
[33] Chris Bailey-Kellogg,et al. Design and analysis of immune-evading enzymes for ADEPT therapy. , 2012, Protein engineering, design & selection : PEDS.
[34] Ronit Mazor,et al. Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A , 2012, Proceedings of the National Academy of Sciences.
[35] Wolfgang Aehle,et al. A β-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy , 2005, Molecular Cancer Therapeutics.